Philip James Wealth Mangement LLC Purchases 66,341 Shares of Organon & Co. (NYSE:OGN)

Philip James Wealth Mangement LLC grew its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 8.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 870,603 shares of the company's stock after purchasing an additional 66,341 shares during the period. Organon & Co. makes up 1.7% of Philip James Wealth Mangement LLC's investment portfolio, making the stock its 7th biggest holding. Philip James Wealth Mangement LLC owned about 0.34% of Organon & Co. worth $12,989,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Prospera Private Wealth LLC bought a new stake in Organon & Co. during the 3rd quarter worth approximately $25,000. Horizon Bancorp Inc. IN raised its holdings in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock valued at $25,000 after buying an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC boosted its holdings in shares of Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company's stock worth $45,000 after purchasing an additional 2,315 shares during the period. Trust Co. of Vermont increased its stake in shares of Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company's stock valued at $50,000 after buying an additional 1,372 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after purchasing an additional 672 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Performance

OGN traded up $0.40 on Thursday, reaching $15.69. The stock had a trading volume of 2,212,868 shares, compared to its average volume of 2,836,317. The company has a market cap of $4.04 billion, a P/E ratio of 4.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.76. The business's 50-day moving average price is $15.35 and its two-hundred day moving average price is $17.32. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Sell-side analysts forecast that Organon & Co. will post 3.78 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.14%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.'s payout ratio is currently 33.63%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.